Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

Journal of Lipid Research

Volumn 52, Issue 12, 2011, Pages 2169-2176

  Cao, Guoqing ^a   Beyer, Thomas P ^a   Zhang, Youyan ^a   Schmidt, Robert J ^a   Chen, Yan Q ^a   Cockerham, Sandra L ^a   Zimmerman, Karen M ^a   Karathanasis, Sotirios K ^a   Cannady, Ellen A ^a   Fields, Todd ^a   Mantlo, Nathan B ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

CETP; Cholesterol; Cholesterol metabolism; Drug therapy; Lipoproteins metabolism

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANACETRAPIB; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 11B1; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; LY 2484595; MESSENGER RNA; RECOMBINANT CHOLESTEROL ESTER TRANSFER PROTEIN; RECOMBINANT PROTEIN; TORCETRAPIB; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MONITORING; CANCER CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME IMMUNOASSAY; EX VIVO STUDY; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HYPERTENSION; IC 50; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SINGLE DRUG DOSE; TRANSGENIC MOUSE;

ALDOSTERONE; ANIMALS; BENZODIAZEPINES; BLOOD PRESSURE; CELL LINE, TUMOR; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; MALE; MICE; MICE, INBRED NOD; RATS; SUBSTRATE SPECIFICITY;

EID: 81855206655     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M018069     Document Type: Article

References (39)

1. Gordon, D. J., J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala, and H. A. Tyroler. 1989. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 79: 8-15. (Pubitemid 19043669)
2. Boden, W. E. 2000. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High - Density Lipoprotein Intervention Trial. Am. J. Cardiol. 86: 19L-22L.
3. Lewis, G. F., and D. J. Rader. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96: 1221-1232. (Pubitemid 40962099)
4. Cockerill, G. W., K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter. 1995. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 15: 1987-1994.
5. Negre-Salvayre, A., N. Dousset, G. Ferretti, T. Bacchetti, G. Curatola, and R. Salvayre. 2006. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic. Biol. Med. 41: 1031-1040. (Pubitemid 44348872)
6. Mineo, C., H. Deguchi, J. H. Griffin, and P. W. Shaul. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98: 1352-1364. (Pubitemid 43948059)
7. Tall, A. R., X. Jiang, Y. Luo, and D. Silver. 2000. 1999 George Lyman Duff memorial lecture: lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20: 1185-1188. (Pubitemid 30262916)
8. Boekholdt, S. M., and J. F. Thompson. 2003. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res. 44: 1080-1093. (Pubitemid 37279626)
9. Thompson, A., E. Di Angelantonio, N. Sarwar, S. Erqou, D. Saleheen, R. P. Dullaart, B. Keavney, Z. Ye, and J. Danesh. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 299: 2777-2788. (Pubitemid 351846853)
10. Sugano, M., N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima. 1998. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J. Biol. Chem. 273: 5033-5036. (Pubitemid 28108660)
11. Rittershaus, C. W., D. P. Miller, L. J. Thomas, M. D. Picard, C. M. Honan, C. D. Emmett, C. L. Pettey, H. Adari, R. A. Hammond, D. T. Beattie, et al. 2000. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20: 2106-2112.
12. Marotti, K. R., C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature. 364: 73-75. (Pubitemid 23233459)
13. Herrera, V. L., S. C. Makrides, H. X. Xie, H. Adari, R. M. Krauss, U. S. Ryan, and N. Ruiz-Opazo. 1999. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat. Med. 5: 1383-1389.
14. Okamoto, H., F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai. 2000. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 406: 203-207. (Pubitemid 30469005)
15. Morehouse, L. A., E. D. Sugarman, P. A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici. 2007. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J. Lipid Res. 48: 1263-1272. (Pubitemid 47312028)
16. Föger, B., M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J. Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, et al. 1999. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 274: 36912-36920.
17. Ranalletta, M., K. K. Bierilo, Y. Chen, D. Milot, Q. Chen, E. Tung, C. Houde, N. H. Elowe, M. Garcia-Calvo, G. Porter, et al. 2010. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J. Lipid Res. 51: 2739-2752.
18. Clark, R. W., R. B. Ruggeri, D. Cunningham, and M. J. Bamberger. 2006. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J. Lipid Res. 47: 537-552. (Pubitemid 43345595)
19. Clark, R. W., T. A. Sutfin, R. B. Ruggeri, A. T. Willauer, E. D. Sugarman, G. Magnus-Aryitey, P. G. Cosgrove, T. M. Sand, R. T. Wester, J. A. Williams, M. E. Perlman, and M. J. Bamberger. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24: 490-497. (Pubitemid 38326143)
20. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515.
21. de Grooth, G. J., J. A. Kuivenhoven, A. F. Stalenhoef, J. de Graaf, A. H. Zwinderman, J. L. Posma, A. van Tol, and J. J. Kastelein. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105: 2159-2165.
22. Kuivenhoven, J. A., G. J. de Grooth, H. Kawamura, A. H. Klerkx, F. Wilhelm, M. D. Trip, and J. J. Kastelein. 2005. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95: 1085-1088. (Pubitemid 40544314)
23. Krishna, R., M. S. Anderson, A. J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D. M. Bloomfield, et al. 2007. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two doubleblind, randomised placebo-controlled phase I studies. Lancet. 370: 1907-1914. (Pubitemid 350192656)
24. Krishna, R., A. Garg, D. Panebianco, J. Cote, A. J. Bergman, P. Van Hoydonck, T. Laethem, K. Van Dyck, J. Chen, C. Chavez-Eng, et al. 2009. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br. J. Clin. Pharmacol. 68: 535-545.
25. Cannon, C. P., S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, et al. 2010. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N. Engl. J. Med. 363: 2406-2415.
26. Bisoendial, R. J., G. K. Hovingh, K. El Harchaoui, J. H. Levels, S. Tsimikas, K. Pu, A. E. Zwinderman, J. A. Kuivenhoven, J. J. Kastelein, and E. S. Stroes. 2005. Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia. Arterioscler. Thromb. Vasc. Biol. 25: e133-e134.
27. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, C. L. Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall, and B. Brewer. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122. (Pubitemid 350146106)
28. Hu, X., J. D. Dietz, C. Xia, D. R. Knight, W. T. Loging, A. H. Smith, H. Yuan, D. A. Perry, and J. Keiser. 2009. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein (CETP) inhibition. Endocrinology. 22: 11-19.
29. Forrest, M. J., D. Bloomfield, R. J. Briscoe, P. N. Brown, A. M. Cumiskey, J. Ehrhart, J. C. Hershey, W. J. Keller, X. Ma, H. E. McPherson, E. Messina, L. B. Peterson, W. Sharif-Rodriguez, P. K. Siegl, P. J. Sinclair, C. P. Sparrow, A. S. Stevenson, S. Y. Sun, C. Tsai, H. Vargas, M. Walker, 3rd, S. H. West, V. White, and R. F. Woltmann. 2008. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154: 1465-1473.
30. Nicholls, S. J., E. M. Tuzcu, D. M. Brennan, J. C. Tardif, and S. E. Nissen. 2008. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 118: 2506-2514.
31. Barter, P. 2009. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am. J. Cardiol. 104: 10E-15E.
32. Bisgaier, C. L., L. L. Minton, A. D. Essenburg, A. White, and R. Homan. 1993. Use of fluorescent cholesteryl ester microemulsions in cholesteryl ester transfer protein assays. J. Lipid Res. 34: 1625-1634. (Pubitemid 23264335)
33. Burris, T. P., P. D. Pelton, L. Zhou, M. C. Osborne, E. Cryan, and K. T. Demarest. 1999. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. Mol. Endocrinol. 13: 410-417. (Pubitemid 29113873)
34. Grass, D. S., U. Saini, R. H. Felkner, R. E. Wallace, W. J. Lago, S. G. Young, and M. E. Swanson. 1995. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans. J. Lipid Res. 36: 1082-1091.
35. Rubin, E. M., B. Y. Ishida, S. M. Clift, and R. M. Krauss. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. USA. 88: 434-438. (Pubitemid 21915479)
36. Agellon, L. B., A. Walsh, T. Hayek, P. Moulin, X. C. Jiang, S. A. Shelanski, J. L. Breslow, and A. R. Tall. 1991. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266: 10796-10801. (Pubitemid 21906874)
37. Hayek, T., T. Chajek-Shaul, A. Walsh, L. B. Agellon, P. Moulin, A. R. Tall, and J. L. Breslow. 1992. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J. Clin. Invest. 90: 505-510.
38. Rye, K. A., C. A. Bursill, G. Lambert, F. Tabet, and P. J. Barter. 2009. The metabolism and anti-atherogenic properties of HDL. J. Lipid Res. 50 (Suppl) : S195-S200.
39. Niesor, E. J., C. Magg, N. Ogawa, H. Okamoto, E. von der Mark, H. Matile, G. Schmid, R. G. Clerc, E. Chaput, D. Blum-Kaelin, et al. 2010. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J. Lipid Res. 51: 3443-3454.